Abstract
Paul Newton and colleagues argue that public health, and not intellectual property or trade issues, should be the prime consideration in defining and combating counterfeit medicines, and that the World Health Organization (WHO) should take a more prominent role.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Consumer Product Safety
-
Counterfeit Drugs / adverse effects*
-
Counterfeit Drugs / classification
-
Counterfeit Drugs / supply & distribution
-
Delivery of Health Care / legislation & jurisprudence
-
Delivery of Health Care / standards
-
Developing Countries*
-
Drug Industry / legislation & jurisprudence
-
Drug Industry / standards*
-
Government Regulation
-
Intellectual Property
-
International Agencies / legislation & jurisprudence
-
International Cooperation / legislation & jurisprudence
-
Legislation, Drug
-
Pharmaceutical Preparations / standards*
-
Public Health / standards*
-
Quality Control
Substances
-
Counterfeit Drugs
-
Pharmaceutical Preparations